Let's map the integration points.

A scoped, time-boxed trial on one service line — usually oncology or cardiology — where AGenomics connects to your existing systems, surfaces real-time genomic safety alerts to clinicians, and scores claims before submission, so your team can measure the clinical and financial impact on your own data before making any wider decision.

The pilot is structured to de-risk the decision, not to require faith in one. Commercial terms are agreed up front and deliberately kept low-friction; there is no large fixed technology cost and no hospital-wide licence required to run it. Exact terms are confirmed in your pilot agreement.

No. The pilot carries no obligation to adopt AGenomics hospital-wide, or at all. It is explicitly designed so the case for wider adoption is proven with your own data first — the decision to continue, expand, or stop is entirely yours at the end of the 90 days.

Typically a small group: the service-line clinical lead, the CIO or data officer, and the RCM/finance lead. Because nothing is ripped out or replaced, the approval footprint is far smaller than a normal health-IT procurement.

Because AGenomics connects through standards you already run — HL7 v2.x, FHIR R4, and CDS Hooks — integration is a matter of weeks, not quarters. The main variables are your internal scheduling and information-security review, not the technology.

A single endpoint URL added to your existing HIS configuration, access to the relevant HL7/FHIR message flows for the chosen service line, and a short information-security review. Your team does not build new infrastructure or stand up new systems.

No. AGenomics sits upstream of claim submission and does not touch your existing clearinghouse connection, your billing workflow, or your contracts with UAE health insurance companies. Your clinicians keep their existing prescribing screen; your billers keep their existing queue.

No. Alerts appear inside the prescribing screen they already use, via CDS Hooks. There is no separate portal to log into and nothing new to remember to check. Onboarding for clinicians is minimal by design.

Only the genomic and clinical data relevant to the chosen service line — the same HL7/FHIR data your systems already produce, plus genomic records queried from the national exchanges (Malaffi, Nabidh) using the patient's Emirates ID, subject to consent. Access is scoped to the pilot and its purpose.

The final AGenomics product is edge-deployed on-premise, meaning genomic data is processed inside your own firewall and never leaves the building. For the POC and this 90-day pilot specifically, AGenomics runs on a UAE-specific cloud instance (Microsoft Azure, UAE North region) so that all data remains inside the UAE for the duration of the trial. In both cases, data stays within UAE jurisdiction.

Compliance is built into the architecture, not added as a policy document. Consent is checked at ingestion before any processing occurs, processing is scoped to clinical and billing purpose, data is minimised at the gate, and residency is guaranteed by where the system runs — on-premise in production, and on a UAE cloud instance during the pilot. Cross-hospital learning, where used, happens through federated model updates rather than any pooling of patient records.

Data access is limited to the pilot's defined clinical and billing purpose, resolved against verified identity, and gated on consent. Un-consented records are blocked from downstream processing. No patient records are shared with other hospitals.

Yes. Every clinical alert and every claim score traces back to a specific, versioned rule in the ARIS rule store, so any question from your compliance team, an auditor, or a UAE health insurance company has a concrete, documented answer rather than a black-box result.

The pilot works best where genomic prescribing risk and claim-denial risk are highest — most commonly oncology or cardiology. We help you pick the line where the 90-day signal will be clearest, based on your own case mix.

When a clinician opens a chart, AGenomics has already loaded any existing pharmacogenomic profile in the background. If a prescribed medication carries a known drug–gene risk for that patient, the clinician sees a severity-graded alert — a hard stop for genuinely contraindicated combinations, a quieter note for dosing considerations — with the reasoning and a suitable alternative, before the order is completed.

Each claim in the chosen service line is scored 0-to-100 before it leaves your building, against live UAE health-insurer rules, across eligibility, coding accuracy, medical necessity, pre-authorisation linkage, genomic justification, and fraud/waste/abuse risk. Where something is missing, the system flags exactly what — and for many gaps offers a one-click fix that writes the medical-necessity narrative from the genomic evidence already captured.

Only within limits you set. You decide whether claims above the scoring threshold auto-submit or simply surface as “ready to submit” for your team to review. Nothing is forced — the pilot is configured to match your risk appetite.

No — that is a deliberate design goal. Alerts are graded by real clinical severity, so clinicians see a hard stop only where it genuinely matters and lighter notes elsewhere, rather than a wall of low-value pop-ups that trains people to click through them.

Success metrics are agreed at the start, on your own baseline. Typical measures include movement in denial rate for the service line, recovered or protected revenue, the number of genomic prescribing risks surfaced before an order was completed, and time saved per claim in the billing team. You see your own numbers, not projections.

The pilot runs on your live data for the chosen service line. (The public demo and screenshots on this site use synthetic, fictional data — no real patient information — and are for illustration only.)

You receive a results summary against the agreed metrics and make a decision: expand to more service lines, continue as-is, pause, or stop. There is no default that commits you to anything. If you choose to expand, the move toward the on-premise edge deployment is planned with your IT team at that point.

Yes. The pilot can be wound down on reasonable notice as set out in the pilot agreement, and data handling on termination is defined in that agreement.

Your patient data remains yours throughout. Terms covering data handling, retention, and any aggregate or federated learning are set out transparently in the pilot agreement before you begin.